Assessment of priorities, quality, and inclusivity of digital therapeutics trials in China
Abstract Digital therapeutics (DTx) are software-driven solutions for prevention, treatment, and management of medical conditions. Despite a pro-DTx momentum in China, global DTx trial assessments overlooked the country. We identified 756 DTx trials in China and analyzed their characteristics and qu...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-02-01
|
| Series: | npj Digital Medicine |
| Online Access: | https://doi.org/10.1038/s41746-025-01477-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823861573891915776 |
|---|---|
| author | Ziming Wang Xinxin Xia Weijia Lu Yuguo Ye Jin Xu |
| author_facet | Ziming Wang Xinxin Xia Weijia Lu Yuguo Ye Jin Xu |
| author_sort | Ziming Wang |
| collection | DOAJ |
| description | Abstract Digital therapeutics (DTx) are software-driven solutions for prevention, treatment, and management of medical conditions. Despite a pro-DTx momentum in China, global DTx trial assessments overlooked the country. We identified 756 DTx trials in China and analyzed their characteristics and quality parameters. Over 70% were funded by governments, hospitals, and universities, with tertiary hospitals in eastern China leading most trials. 44.8% used automated DTx, with 39.2% DTx-guided. Most trials focused on management (52.5%) and treatment (38.1%), with few on prevention (9.4%). Mental, behavioral, or neurodevelopmental disorders represented the leading condition category of focus. Recent declines in median sample size, median duration, and mean number of sites were noted. Only 18% of trials were at low overall risk of bias. While recognizing the rapid development of DTx trials in China, we call for better trial design and methodological rigor, prioritization of preventive and primary care, wider condition category scope, and higher inclusivity. |
| format | Article |
| id | doaj-art-8768e7292c7544de86f589bac7441c40 |
| institution | Kabale University |
| issn | 2398-6352 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Digital Medicine |
| spelling | doaj-art-8768e7292c7544de86f589bac7441c402025-02-09T12:55:40ZengNature Portfolionpj Digital Medicine2398-63522025-02-01811810.1038/s41746-025-01477-6Assessment of priorities, quality, and inclusivity of digital therapeutics trials in ChinaZiming Wang0Xinxin Xia1Weijia Lu2Yuguo Ye3Jin Xu4China Center for Health Development Studies, Peking University, Xueyuan RoadChina Center for Health Development Studies, Peking University, Xueyuan RoadChina Center for Health Development Studies, Peking University, Xueyuan RoadChina Center for Health Development Studies, Peking University, Xueyuan RoadChina Center for Health Development Studies, Peking University, Xueyuan RoadAbstract Digital therapeutics (DTx) are software-driven solutions for prevention, treatment, and management of medical conditions. Despite a pro-DTx momentum in China, global DTx trial assessments overlooked the country. We identified 756 DTx trials in China and analyzed their characteristics and quality parameters. Over 70% were funded by governments, hospitals, and universities, with tertiary hospitals in eastern China leading most trials. 44.8% used automated DTx, with 39.2% DTx-guided. Most trials focused on management (52.5%) and treatment (38.1%), with few on prevention (9.4%). Mental, behavioral, or neurodevelopmental disorders represented the leading condition category of focus. Recent declines in median sample size, median duration, and mean number of sites were noted. Only 18% of trials were at low overall risk of bias. While recognizing the rapid development of DTx trials in China, we call for better trial design and methodological rigor, prioritization of preventive and primary care, wider condition category scope, and higher inclusivity.https://doi.org/10.1038/s41746-025-01477-6 |
| spellingShingle | Ziming Wang Xinxin Xia Weijia Lu Yuguo Ye Jin Xu Assessment of priorities, quality, and inclusivity of digital therapeutics trials in China npj Digital Medicine |
| title | Assessment of priorities, quality, and inclusivity of digital therapeutics trials in China |
| title_full | Assessment of priorities, quality, and inclusivity of digital therapeutics trials in China |
| title_fullStr | Assessment of priorities, quality, and inclusivity of digital therapeutics trials in China |
| title_full_unstemmed | Assessment of priorities, quality, and inclusivity of digital therapeutics trials in China |
| title_short | Assessment of priorities, quality, and inclusivity of digital therapeutics trials in China |
| title_sort | assessment of priorities quality and inclusivity of digital therapeutics trials in china |
| url | https://doi.org/10.1038/s41746-025-01477-6 |
| work_keys_str_mv | AT zimingwang assessmentofprioritiesqualityandinclusivityofdigitaltherapeuticstrialsinchina AT xinxinxia assessmentofprioritiesqualityandinclusivityofdigitaltherapeuticstrialsinchina AT weijialu assessmentofprioritiesqualityandinclusivityofdigitaltherapeuticstrialsinchina AT yuguoye assessmentofprioritiesqualityandinclusivityofdigitaltherapeuticstrialsinchina AT jinxu assessmentofprioritiesqualityandinclusivityofdigitaltherapeuticstrialsinchina |